Han Gyeol Kim1,2, Ji-Youn Sung2, Kiyong Na2, So-Woon Kim3. 1. Department of Medicine, Graduate School, Kyung Hee University, Seoul, Republic of Korea. 2. Department of Pathology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Republic of Korea. 3. Department of Pathology, Kyung Hee University Hospital, Kyung Hee University College of Medicine, Seoul, Republic of Korea sowoonkim86@gmail.com.
Abstract
BACKGROUND/AIM: Histone modification is associated with tumorigenesis and cancer progression. Recent studies have revealed the prognostic value of histone modification; however, its prognostic role in distal bile duct cancer remains unclear. PATIENTS AND METHODS: We analyzed the expression of H3K9me3, H4K20me3, and H3K36me3 and its correlation with survival outcomes in resected samples from 88 patients with distal bile duct cancer. RESULTS: Low expression rates of H3K9me3, H4K20me3, and H3K36me3 were significantly associated with poor overall survival (p=0.003, 0.008, and 0.047, respectively) and event-free survival (p=0.03 for H3K9m3). Additionally, low-expression of H3K9me3 was an independent poor prognostic indicator (p<0.001; HR=7.85; 95% CI=2.693-22.883). CONCLUSION: H3K9me3 was an independent poor prognostic factor in distal common bile duct cancer. Our results suggest that histone markers are potential prognostic markers and provide better management for patients at risk for an aggressive course of disease. Copyright
BACKGROUND/AIM: Histone modification is associated with tumorigenesis and cancer progression. Recent studies have revealed the prognostic value of histone modification; however, its prognostic role in distal bile duct cancer remains unclear. PATIENTS AND METHODS: We analyzed the expression of H3K9me3, H4K20me3, and H3K36me3 and its correlation with survival outcomes in resected samples from 88 patients with distal bile duct cancer. RESULTS: Low expression rates of H3K9me3, H4K20me3, and H3K36me3 were significantly associated with poor overall survival (p=0.003, 0.008, and 0.047, respectively) and event-free survival (p=0.03 for H3K9m3). Additionally, low-expression of H3K9me3 was an independent poor prognostic indicator (p<0.001; HR=7.85; 95% CI=2.693-22.883). CONCLUSION: H3K9me3 was an independent poor prognostic factor in distal common bile duct cancer. Our results suggest that histone markers are potential prognostic markers and provide better management for patients at risk for an aggressive course of disease. Copyright
Authors: Liu Yang; Li Xia; Daniel Y Wu; Hengbin Wang; Howard A Chansky; William H Schubach; Dennis D Hickstein; Yi Zhang Journal: Oncogene Date: 2002-01-03 Impact factor: 9.867
Authors: Michelle L DeOliveira; Steven C Cunningham; John L Cameron; Farin Kamangar; Jordan M Winter; Keith D Lillemoe; Michael A Choti; Charles J Yeo; Richard D Schulick Journal: Ann Surg Date: 2007-05 Impact factor: 12.969
Authors: Arnaud Van Den Broeck; Elisabeth Brambilla; Denis Moro-Sibilot; Sylvie Lantuejoul; Christian Brambilla; Beatrice Eymin; Sylvie Gazzeri Journal: Clin Cancer Res Date: 2008-10-30 Impact factor: 12.531
Authors: Thai H Ho; Payal Kapur; Richard W Joseph; Daniel J Serie; Jeanette E Eckel-Passow; Pan Tong; Jing Wang; Erik P Castle; Melissa L Stanton; John C Cheville; Eric Jonasch; James Brugarolas; Alexander S Parker Journal: Mod Pathol Date: 2015-10-30 Impact factor: 7.842
Authors: Johannes Byrling; Roland Andersson; Agata Sasor; Gert Lindell; Daniel Ansari; Johan Nilsson; Bodil Andersson Journal: Ann Gastroenterol Date: 2017-06-20
Authors: M Rodriguez-Paredes; A Martinez de Paz; L Simó-Riudalbas; S Sayols; C Moutinho; S Moran; A Villanueva; M Vázquez-Cedeira; P A Lazo; F Carneiro; C S Moura; J Vieira; M R Teixeira; M Esteller Journal: Oncogene Date: 2013-06-17 Impact factor: 9.867